1. Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF.

    Transplantation 93(7):676 (2012) PMID 22262127

    Immunologic rejection is a major barrier to successful long-term outcomes in clinical transplantation. The importance of B lymphocytes-and their secretory products, alloantibodies-in the pathogenesis of allograft rejection is accepted. Furthermore, it is now clear that the dominant regulator of ...
  2. Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF.

    Transplantation 93(7):676 (2012) PMID 22262127

    Immunologic rejection is a major barrier to successful long-term outcomes in clinical transplantation. The importance of B lymphocytes-and their secretory products, alloantibodies-in the pathogenesis of allograft rejection is accepted. Furthermore, it is now clear that the dominant regulator of ...
  3. Acquisition of humoral transplantation tolerance upon de novo emergence of B lymphocytes.

    Journal of Immunology 186(1):614 (2011) PMID 21084661

    A major obstacle to transplantation tolerance is humoral immunity. In this paper, we demonstrate that the intrinsic developmental propensity of the B lymphocyte compartment for acquisition of self-tolerance can be harnessed to induce humoral unresponsiveness to transplanted alloantigens. In the ...
  4. Acquisition of humoral transplantation tolerance upon de novo emergence of B lymphocytes.

    Journal of Immunology 186(1):614 (2011) PMID 21084661

    A major obstacle to transplantation tolerance is humoral immunity. In this paper, we demonstrate that the intrinsic developmental propensity of the B lymphocyte compartment for acquisition of self-tolerance can be harnessed to induce humoral unresponsiveness to transplanted alloantigens. In the ...
  5. A novel CD93 polymorphism in non-obese diabetic (NOD) and NZB/W F1 mice is linked to a CD4+ iNKT cell deficient state.

    Immunogenetics 62(6):397 (2010) PMID 20387063 PMCID PMC2875467

    In the present study, we characterize a polymorphism in the CD93 molecule, originally identified as the receptor for the C1q complement component (i.e., C1qRp, or AA4.1) in non-obese diabetic (NOD) mice. This allele carries a coding polymorphism in the first epidermal growth factor-like domain o...
  6. A novel CD93 polymorphism in non-obese diabetic (NOD) and NZB/W F1 mice is linked to a CD4+ iNKT cell deficient state.

    Immunogenetics 62(6):397 (2010) PMID 20387063 PMCID PMC2875467

    In the present study, we characterize a polymorphism in the CD93 molecule, originally identified as the receptor for the C1q complement component (i.e., C1qRp, or AA4.1) in non-obese diabetic (NOD) mice. This allele carries a coding polymorphism in the first epidermal growth factor-like domain o...
  7. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice.

    Journal of Immunology 181(11):8133 (2008) PMID 19018006 PMCID PMC2586964

    B lymphocytes are required for the pathogenesis of autoimmune diabetes in NOD mice. Previous studies established that a lymphopenic transitional (TR) B cell compartment reduces the competitive constraint on the entry of newly emerging TR B cells into the splenic follicle (FO), thereby disrupting...
  8. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice.

    Journal of Immunology 181(11):8133 (2008) PMID 19018006 PMCID PMC2586964

    B lymphocytes are required for the pathogenesis of autoimmune diabetes in NOD mice. Previous studies established that a lymphopenic transitional (TR) B cell compartment reduces the competitive constraint on the entry of newly emerging TR B cells into the splenic follicle (FO), thereby disrupting...
  9. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates.

    Nature Medicine 13(11):1295 (2007) PMID 17965721

    We found that an induction immunotherapy regimen consisting of rabbit anti-thymocyte globulin (Thymoglobulin) and the monoclonal antibody to CD20 rituximab (Rituxan) promoted long-term islet allograft survival in cynomolgus macaques maintained on rapamycin monotherapy. B lymphocyte reconstitutio...
  10. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates.

    Nature Medicine 13(11):1295 (2007) PMID 17965721

    We found that an induction immunotherapy regimen consisting of rabbit anti-thymocyte globulin (Thymoglobulin) and the monoclonal antibody to CD20 rituximab (Rituxan) promoted long-term islet allograft survival in cynomolgus macaques maintained on rapamycin monotherapy. B lymphocyte reconstitutio...
  11. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection.

    Journal of Immunology 177(11):7715 (2006) PMID 17114442

    Acute allograft rejection requires the activation of alloreactive CD4 T cells. Despite the capacity of B cells to act as potent APCs capable of activating CD4 T cells in vivo, their role in the progression of acute allograft rejection was unclear. To determine the contribution of B cell APC func...
  12. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection.

    Journal of Immunology 177(11):7715 (2006) PMID 17114442

    Acute allograft rejection requires the activation of alloreactive CD4 T cells. Despite the capacity of B cells to act as potent APCs capable of activating CD4 T cells in vivo, their role in the progression of acute allograft rejection was unclear. To determine the contribution of B cell APC func...
  13. Alloreactive CD4 T cell activation in vivo: an autonomous function of the indirect pathway of alloantigen presentation.

    Journal of Immunology 171(12):6502 (2003) PMID 14662850

    Activation of alloreactive CD4 T cells occurs via the direct and indirect pathways of alloantigen presentation. A novel TCR/alloantigen transgenic system was designed that permitted in vivo visualization of CD4 T cell priming through these pathways. When both pathways of alloantigen presentation...
  14. Alloreactive CD4 T cell activation in vivo: an autonomous function of the indirect pathway of alloantigen presentation.

    Journal of Immunology 171(12):6502 (2003) PMID 14662850

    Activation of alloreactive CD4 T cells occurs via the direct and indirect pathways of alloantigen presentation. A novel TCR/alloantigen transgenic system was designed that permitted in vivo visualization of CD4 T cell priming through these pathways. When both pathways of alloantigen presentation...
  15. B cell tolerance: A C3 dependent process

    Molecular Immunology 35(6):371 (1998)